Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Research & Development is the aggregate amount of research and development expenses during the year. Adicon Holdings's Research & Development for the
six
months ended in Dec. 2025 was €5.9 Mil.
Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €12.5 Mil.
Adicon Holdings (FRA:K0U) Research & Development Explanation
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Adicon Holdings Research & Development Related Terms
Adicon Holdings Research & Development Historical Data
* Premium members only.
The historical data trend for Adicon Holdings's Research & Development can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicon Holdings Research & Development Calculation
This is the expense the company spent on research and development.
Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €12.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Research & Development of €12.5 Mil mean?
Adicon Holdings (FRA:K0U) has a Research & Development of €12.5 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Adicon Holdings and its competitors.
Is Adicon Holdings' Research & Development too high?
Adicon Holdings' current Research & Development is €12.5 Mil. Overall, Adicon Holdings has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Adicon Holdings' Research & Development compare to TMO and DHR?
Adicon Holdings' Research & Development of €12.5 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Adicon Holdings and its competitors. Adicon Holdings's current Research & Development is €12.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicon Holdings stock overvalued right now?
Adicon Holdings (FRA:K0U) has a current Research & Development of €12.5 Mil. The stock's GF Value™ is €0.77, compared to a current price of €0.36 — trading 53.5% below its estimated fair value. The current Research & Development is €12.5 Mil. Adicon Holdings' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Adicon Holdings (FRA:K0U), the current Research & Development is €12.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicon Holdings (FRA:K0U) Overvalued in 2026?
Based on GuruFocus' analysis, Adicon Holdings stock appears to be undervalued.
The current stock price of €0.36 is trading 53.5% below its estimated GF Value™ of €0.77.
Key valuation signals for FRA:K0U:
Research & Development: €12.5 Mil
GF Value™: €0.77 vs. price of €0.36 (53.5% below fair value)
No single metric tells the full story. See the FRA:K0U stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicon Holdings Ltd is a ICL service provider in China. It offers comprehensive testing services to hospitals and health check centers through an integrated network of self-operated laboratories across China. Its testing services platform includes clinical laboratories, pathology laboratories, reproductive genetics laboratories, gene laboratories, and mass spectrometry laboratories, consisting of over 4,000 medical diagnostic tests, the introduction of over 300 new high-end diagnostic tests.
75GF Score
Get the complete analysis for FRA:K0U
Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K0U has been successfully added to your 
